GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Alembic Pharmaceuticals Ltd

Alembic Pharma's Q2 FY27 Consolidated Revenue Jumps 36% to Rs. 2603 Cr

RESULTS ▲ Positive Development LOW RISK
📅 Filed on BSE: 04 Nov 2026, 02:34 PM IST  ·  BSE ID: 53212c89-9386-403b-9f1f-ea2767f6d2da
View Original BSE Filing (PDF)
💡
In Simple Terms
Alembic Pharma's latest quarterly results show a significant increase in sales and profits compared to last year.
🤖 AI Summary
  • Alembic Pharmaceuticals reported consolidated revenue from operations increased 36% YoY to Rs. 2603 Cr for Q2 FY27.
  • Profit After Tax for Q2 FY27 was Rs. 335 Cr, marking an 81% increase year-on-year.
  • EBITDA rose 78% YoY to Rs. 578 Cr in Q2 FY27, achieving a 22% margin.
  • US Formulations business revenue grew 77% to Rs. 1003 Cr, with 3 new launches in the US market.
  • India Branded Business delivered 14% YoY growth, reaching Rs. 725 Cr in revenue for the quarter.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Consolidated Revenue from Operations Q2 FY27
Rs. 2603 Cr
36%
EBITDA Q2 FY27
Rs. 578 Cr
78%
Profit After Tax Q2 FY27
Rs. 335 Cr
81%
India Branded Business Q2 FY27
Rs. 725 Cr
14%
US Formulations Business Q2 FY27
Rs. 1003 Cr
77%
Ex-US Business Q2 FY27
Rs. 440 Cr
12%
API Business Q2 FY27
Rs. 436 Cr
39%
Total Revenue H1 FY27
Rs. 4753 Cr
31%
🏢 How This Affects the Company
📈
Business Impact
The company's market position is strengthened by broad-based growth across US, India Branded, Ex-US, and API segments, reflecting consistent execution and new launches.
💰
Financial Impact
Improved profitability is evident from the 81% YoY increase in Profit After Tax and 78% rise in EBITDA, contributing to stronger financial performance.
⚙️
Operational Impact
The launch of 3 new products in the US market during the quarter indicates active product development and market expansion efforts.
👥 What This Means For Shareholders
✅
Action Required
No action required by shareholders based on this financial results filing.
👤
Who Is Affected
All shareholders are affected by the company's financial performance, as reflected in the Q2 FY27 consolidated revenue of Rs. 2603 Cr and PAT of Rs. 335 Cr.
🔍
Management Signal
Management indicates a focus on sustained growth and improved profitability, driven by execution across diverse markets and new product introductions.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
Q3 FY27 financial results — assess sustainability of revenue and profit growth.
Regulatory approvals for new ANDAs — monitor pipeline progress and market entry.
Updates on US market launches — track performance of recently introduced products.
LOW RISK The filing reports strong financial performance with broad-based growth, indicating low immediate risk.
💡 Investor Takeaway
Alembic Pharmaceuticals reported a 36% YoY increase in consolidated revenue from operations to Rs. 2603 Cr and an 81% YoY rise in Profit After Tax to Rs. 335 Cr for Q2 FY27. US Formulations business grew 77% to Rs. 1003 Cr, with India Branded up 14% to Rs. 725 Cr.
⚖️ Strengths & Concerns

✅ Positives

  • Consolidated revenue from operations increased by 36% YoY to Rs. 2603 Cr in Q2 FY27, demonstrating strong top-line growth.
  • Profit After Tax grew 81% YoY to Rs. 335 Cr, alongside a 78% increase in EBITDA to Rs. 578 Cr, showing enhanced profitability.
📅 Company Track Record
Alembic Pharma's Q2 FY27 consolidated revenue increased by 36% YoY to Rs. 2,603.48 Crores, following a 26% YoY revenue increase to Rs. 2150 Cr in Q1 FY27. Profit for Q2 FY27 rose 81%, after a 12% profit increase in Q1 FY27.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was Alembic Pharmaceuticals' consolidated revenue in Q2 FY27?
Alembic Pharmaceuticals reported consolidated revenue from operations of Rs. 2603 Cr in Q2 FY27, an increase of 36% year-on-year.
What was Alembic Pharmaceuticals' Profit After Tax for Q2 FY27?
Profit After Tax for Alembic Pharmaceuticals in Q2 FY27 was Rs. 335 Cr, which is an 81% increase year-on-year.
How did Alembic Pharmaceuticals' US Formulations business perform in Q2 FY27?
The US Formulations business of Alembic Pharmaceuticals grew by 77% to Rs. 1003 Cr in Q2 FY27, with 3 product launches in the US market during the quarter.
What was the growth in Alembic Pharmaceuticals' India Branded Business for Q2 FY27?
Alembic Pharmaceuticals' India Branded Business delivered a 14% year-on-year growth, achieving Rs. 725 Cr in revenue for Q2 FY27.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.